CaMKIIδ-dependent dysregulation of atrial Na+ homeostasis promotes pro-arrhythmic activity in an obstructive sleep

Philipp Hegner1, Florian Ofner1, Benedikt Schaner1,2

  • 1Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

PubMed
Abstract

Insights

Obstructive sleep apnea increases atrial sodium levels and arrhythmia risk via a CaMKIIδ-dependent pathway. This finding offers potential new therapeutic targets for treating sleep apnea-related heart conditions.

Area of Science:

  • Cardiology
  • Sleep Medicine
  • Molecular Biology

Background:

  • Obstructive sleep apnea (OSA) is linked to arrhythmias like atrial fibrillation.
  • Reactive oxygen species (ROS) increase late sodium current via CaMKIIδ, promoting arrhythmias.
  • The specific impact of OSA on atrial sodium homeostasis remains unclear, complicated by comorbidities.

Purpose of the Study:

  • To investigate the effects of OSA on ROS production, cytosolic sodium levels, and spontaneous arrhythmias in atrial cardiomyocytes.
  • To determine the role of CaMKIIδ in OSA-induced atrial electrophysiological changes.
  • To utilize a comorbidity-free OSA mouse model for precise analysis.

Main Methods:

  • OSA was induced in wild-type and CaMKIIδ-knockout mice using PTFE injections.
  • Atrial cardiomyocytes were analyzed for ROS production using laser-scanning confocal microscopy.
  • Cytosolic sodium concentration and spontaneous arrhythmias were quantified via epifluorescence microscopy.

Main Results:

  • PTFE treatment significantly increased both cytosolic and mitochondrial ROS production.
  • Cytosolic sodium concentration markedly increased in OSA mice, but was protected in CaMKIIδ-knockout mice.
  • Spontaneous calcium release events, indicative of arrhythmia propensity, increased in OSA mice and were reduced in CaMKIIδ-knockout mice.

Conclusions:

  • Atrial sodium concentration and spontaneous calcium release events are elevated in an OSA mouse model.
  • These OSA-induced changes are dependent on CaMKIIδ activity.
  • Targeting the CaMKIIδ pathway may offer therapeutic benefits for OSA-related cardiac issues.